Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

HeartSciences (HSCS) EBIT Margin (2021 - 2025)

HeartSciences (HSCS) has disclosed EBIT Margin for 5 consecutive years, with 85713.23% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin fell 8740121.0% year-over-year to 85713.23%, compared with a TTM value of 2314.37% through Oct 2025, down 363814.0%, and an annual FY2025 reading of 192013.13%, down 15811114.0% over the prior year.
  • EBIT Margin was 85713.23% for Q4 2025 at HeartSciences, up from 98637.84% in the prior quarter.
  • Across five years, EBIT Margin topped out at 9214.54% in Q3 2024 and bottomed at 98637.84% in Q3 2025.
  • Average EBIT Margin over 5 years is 30478.53%, with a median of 25266.6% recorded in 2024.
  • The sharpest move saw EBIT Margin soared 5676700bps in 2024, then plummeted -10785238bps in 2025.
  • Year by year, EBIT Margin stood at 9011.84% in 2021, then crashed by -396bps to 44690.53% in 2022, then grew by 10bps to 40254.95% in 2023, then surged by 104bps to 1687.98% in 2024, then plummeted by -5178bps to 85713.23% in 2025.
  • Business Quant data shows EBIT Margin for HSCS at 85713.23% in Q4 2025, 98637.84% in Q3 2025, and 1061.86% in Q2 2025.